IO Biotech

About:

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Website: http://www.iobiotech.com/

Top Investors: Novo Holdings, RA Capital Management, Novo Nordisk, Samsara BioCapital, Kurma Partners

Description:

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.